PD-1 and LAG-3-positive T cells are associated with clinical outcomes of relapsed/refractory multiple myeloma patients

被引：0
|
作者：
Ming Chen
Jinlian Zhu
Xuedong Yang
Jianxin Yao
Yuqing Liu
Qiang Liu
机构：
[1] Changshu No.2 People’s Hospital,Department of Hematology
[2] Changshu No.2 People’s Hospital,Department of Oncology
[3] Changshu No.1 People’s Hospital,Department of Hematology
来源：
European Journal of Medical Research | / 27卷
关键词：
Relapsed/refractory multiple myeloma; T cell subtype; PD-1; LAG-3;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Impact of Lenalidomide on T cell subset composition and PD-1 phenotype in patients with multiple myeloma
    Danhof, S.
    Schreder, M.
    Knop, S.
    Gogishvili, T.
    Einsele, H.
    Hudecek, M.
    Oncology Research and Treatment, 2015, 38 : 234 - 234
  • [42] Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial
    Maruyama, Dai
    Tobinai, Kensei
    Chou, Takaaki
    Taniwaki, Masafumi
    Shumiya, Yoshihisa
    Iida, Shinsuke
    CANCER SCIENCE, 2018, 109 (10): : 3245 - 3252
  • [43] CLINICAL AND TREATMENT CHARACTERISTICS OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN EUROPE
    Oriol, A.
    Steinmetz, T.
    Patel, V
    Kutikova, L.
    Schmidt, N.
    Hennies, N.
    Thiess, A.
    Kostev, K.
    Leleu, X.
    VALUE IN HEALTH, 2019, 22 : S497 - S498
  • [44] Clinical Efficacy of Velcade/CTD Regimen in Patients with Relapsed or Refractory Multiple Myeloma
    Kim, Y. K.
    Lee, J. J.
    Sohn, S. K.
    Joo, Y. D.
    Shin, H. J.
    Chung, J. S.
    Moon, J. H.
    Chae, Y. S.
    Ahn, J. S.
    Yang, D. H.
    Kim, H. J.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S81 - S81
  • [45] Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Elotuzumab and Daratumumab: A Single Center Experience
    Basher, Fahmin
    Paul, Yonette
    Hoffman, James E.
    BLOOD, 2020, 136
  • [46] Use of venetoclax in t(11;14) positive relapsed/refractory multiple myeloma: A systematic review
    Khan, Wardah Javed
    Ali, Mubeen
    Hashim, Sana
    Nawaz, Huma
    Hashim, Syeda Nafeesa
    Safi, Danish
    Inayat, Arslan
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (03) : 552 - 561
  • [47] Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
    Issa, Ghayas C.
    Bidikian, Aram
    Venugopal, Sangeetha
    Konopleva, Marina
    DiNardo, Courtney D.
    Kadia, Tapan M.
    Borthakur, Gautam
    Jabbour, Elias
    Pemmaraju, Naveen
    Yilmaz, Musa
    Short, Nicholas J.
    Maiti, Abhishek
    Sasaki, Koji
    Masarova, Lucia
    Pierce, Sherry
    Takahashi, Koichi
    Tang, Guilin
    Loghavi, Sanam
    Patel, Keyur
    Andreeff, Michael
    Bhalla, Kapil
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Kantarjian, Hagop
    Daver, Naval
    BLOOD ADVANCES, 2023, 7 (06) : 933 - 942
  • [48] Impact of Daratumumab Refractoriness on Clinical Outcomes Following CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma
    Costa, Bruno
    Rajeeve, Sridevi
    Jurgens, Eric
    Nishimura, Noriko
    Farzana, Tasmin
    Firestone, Ross
    Miller, Kevin
    Lesokhin, Alexander
    Shah, Gunjan
    Korde, Neha
    Tan, Carlyn
    Chung, David
    Landau, Heather
    Scordo, Michael
    Hassoun, Hani
    Maclachlan, Kylee
    Shah, Urvi
    Hultcrantz, Malin
    Hamadeh, Issam
    Giralt, Sergio
    Mailankody, Sham
    Usmani, Saad
    Hashmi, Hamza
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S46 - S46
  • [49] Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma
    Squifflet, Pierre
    Michiels, Stefan
    Siegel, David
    Vij, Ravi
    Jagannath, Sundar
    Saad, Everardo D.
    Rajangam, Kanya
    Ro, Sunhee Kwon
    Buyse, Marc
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (11): : 680 - 686
  • [50] Venetoclax versus bortezomib, in combination with daratumumab and dexamethasone, in patients with t(11;14)-positive relapsed or refractory multiple myeloma
    Kaufman, Jonathan
    Quach, Hang
    Baz, Rachid
    Vangsted, Annette Juul
    Ho, Shir-Jing
    Abildgaard, Niels
    Laubach, Jacob
    Ribrag, Vincent
    Gibbs, Simon
    Medvedova, Eva
    Voorhees, Peter
    Jalaluddin, Muhammad
    Zeng, Jiewei
    Ross, Jeremy
    Wang, Xifeng
    Fleming, Leanne Lash
    Bueno, Orlando
    Luo, Yan
    Bahlis, Nizar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S188 - S189
12345